The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy
Open accessAbstract
The development of inhibitors targeting the programmed cell death 1/B7 homolog 1 (PD-1/B7-H1) (PD) pathway, a mechanism adaptively used by tumors to evade the immune response, has been ground breaking in the treatment of a broad spectrum of advanced cancers, especially solid tumors. Antibody blockade of the PD pathway (anti-PD therapy) repairs this immune deficit in the tumor microenvironment, producing previously unseen durable responses in many patients with advanced-stage cancers, but a large fraction of patients still fail to respond. 1 As clinical responses to anti-PD therapy correlate with the presence of both (B7-H1) expression and immune responses in the tumor, 2 we propose a way of categorizing patients based on Tumor Immunity in the MicroEnvironment (TIME) and discuss its implications in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Self-citation
Cited by
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Self-citationSiglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Wang, J., Sun, J., Liu, L. N., Flies, D. B., Nie, X., Toki, M., Zhang, J., Song, C., Zarr, M., Zhou, X., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0374-x · Cited by 679
Self-citationImmunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Doroshow, D. B., Sanmamed, M. F., Hastings, K., Politi, K., Rimm, D. L., Chen, L., Melero, I., Schalper, K. A., & Herbst, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1538 · Cited by 667
Self-citationTang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 607
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Self-citation
Metadata
- Authors
- Zhang, Y., & Chen, L.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-11-01
- Volume
- 2
- Issue
- 11
- Pages
- 1403
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2488061344
- Cited by
- 168
- References
- 2
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. https://app.cochat.ai/papers/10.1001/jamaoncol.2016.2450
- The paper
- Zhang, Y., & Chen, L. (2016). Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2016.2450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.